Newly Established CYPIN PRODUCTION Addresses Win-Win Situation: Building Bridges Between U.S. BioPharma and China

While major developed markets for biopharmaceuticals and life sciences will grow just 3 percent to 6 percent through 2014, emerging markets are expected to grow between 14 percent and 17 percent. One of these especially vital and growing markets in biopharma is China. End Quote

New York, NY (1888PressRelease) October 26, 2010 - The U.S. needs new distribution channels and China not only has a huge demand for high-quality products, but also increased purchasing power. On the other side, China can provide lower costs and ever-improving standards for producing U.S. drugs/supplements, and for supplying various manufacturers' parts.

Enter Cypin Productions

To help leaders both in the U.S. and China come together, CYPIN PRODUCTION has been established. A unique aspect of CYPIN is its leadership's solid background in, and understanding of, the language and culture of both nations. That in turn helps the company to identify and bring together leaders and visionaries who are shaping collaborations in various pharmaceuticals areas and create key niche conferences.

Among the sample key issues that will be found in CYPIN conferences to build economic opportunities between these two markets:

• FDA/ SFDA (China's regulatory agency): Understanding regulations and approval processes via these agencies.
• Due diligence in finding the right outsourcing partners
• Technology transfer
• Market intelligence: Know-how regarding the other society's language and culture

For more information on CYPIN itself or its upcoming conferences, or for expert resources on this emerging area of interest in biopharma and life sciences, contact Director, Judy Tsui (Twee). Email: judy ( @ ) cypinproduction dot com or phone: 917-338-7778.

###

space

Other Related Press Releases